Cargando…

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons

BACKGROUND: Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an imputed-placebo analysis with estimates of the proportion of warfarin effect preserved by each non vitamin K antagonist oral anticoa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verdecchia, Paolo, Angeli, Fabio, Lip, Gregory Y. H., Reboldi, Gianpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067355/ https://www.ncbi.nlm.nih.gov/pubmed/24955573 http://dx.doi.org/10.1371/journal.pone.0100478

Ejemplares similares

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
por: Reboldi, Gianpaolo, et al.
Publicado: (2009)

Hypertension and myocarditis following COVID-19 vaccination. Two sides of the coin?()
por: Angeli, Fabio, et al.
Publicado: (2023)

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review
por: Violi, Francesco, et al.
Publicado: (2016)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

SARS-CoV-2 vaccines: Lights and shadows
por: Angeli, Fabio, et al.
Publicado: (2021)

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
por: Shimizu, Kazuhiro, et al.
Publicado: (2018)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study
por: Vedovati, Maria Cristina, et al.
Publicado: (2019)

Use of Oral Anticoagulants in Patients with Atrial Fibrillation: Preliminary Data from the Italian Atrial Fibrillation (ITALY-AF) Registry
por: Angeli, Fabio, et al.
Publicado: (2023)

Comparative assessment of angiotensin receptor blockers in different clinical settings
por: Verdecchia, Paolo, et al.
Publicado: (2009)

Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry
por: Angeli, Fabio, et al.
Publicado: (2019)

The revolution of the anti-diabetic drugs in cardiology
por: Verdecchia, Paolo, et al.
Publicado: (2020)

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
por: Angeli, Fabio, et al.
Publicado: (2022)

COVID-19, vaccines and deficiency of ACE(2) and other angiotensinases. Closing the loop on the "Spike effect"
por: Angeli, Fabio, et al.
Publicado: (2022)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Echocardiography in Low‐Risk Hypertensive Patients
por: Mancusi, Costantino, et al.
Publicado: (2019)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications
por: Camelo-Castillo, Anny, et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later
por: Angeli, Fabio, et al.
Publicado: (2021)

The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure()
por: Angeli, Fabio, et al.
Publicado: (2023)

Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials
por: Domek, Magdalena, et al.
Publicado: (2020)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vqq7a1ta367it3u2v5sjsdfe74